Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis: a commentary on the proposed EU pharma regulation

• Till Bärnighausen,
• Albrecht Jahn,
• Astrid Berner-Rodoreda,
• Frank Cobelens,
• Mario Raviglione,
• Jolene Skordis,
• Anne-Mieke Vandamme,
• Günter Froeschl,
• Elil Renganathan,
• Ellen t’Hoen

Affiliations

Till Bärnighausen

Heidelberg Institute of Global Health (HIGH), University Hospital, Heidelberg University, Heidelberg, Germany

Albrecht Jahn

Heidelberg Institute of Global Health (HIGH), University Hospital, Heidelberg University, Heidelberg, Germany

Astrid Berner-Rodoreda

Heidelberg Institute of Global Health (HIGH), University Hospital, Heidelberg University, Heidelberg, Germany

Frank Cobelens

Amsterdam Institute for Global Health & Development (AIGHD) and Department of Global Health, Amsterdam University Medical Centers, Amsterdam, The Netherlands

Mario Raviglione

Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milano, Italy

Jolene Skordis

Institute for Global Health, University College London (UCL), London, UK

Anne-Mieke Vandamme

Clinical and Epidemiological Virology, Institute for the Future, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium

Günter Froeschl

Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany

Elil Renganathan

School of Medical and Life Sciences, Sunway University, Bandar Sunway, Malaysia

Ellen t’Hoen

Medicines Law & Policy, Amsterdam, The Netherlands